Ligand Pharmaceuticals

Yahoo Finance • 10 days ago

What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the... Full story

Yahoo Finance • 19 days ago

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30... Full story

Yahoo Finance • 19 days ago

Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer

Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in the US from Biofrontera and Ferrer Internacional. The topical cream is indicated to treat impetigo, a bacterial... Full story

Yahoo Finance • 22 days ago

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections cause... Full story

Yahoo Finance • 30 days ago

Ligand to Participate in November Investor Conferences

JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcom... Full story

Yahoo Finance • last month

MSTZ, AFSC: Big ETF Outflows

Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the MSTZ ETF, where 7,510,000 units were destroyed, or a 35.7% decrease week over week. And on a percen... Full story

Yahoo Finance • 2 months ago

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) --... Full story

Yahoo Finance • 2 months ago

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc (“Arecor” or the “Company”) Co-development Agreement with US I... Full story

Yahoo Finance • 3 months ago

Notable ETF Inflow Detected - JPLD

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPLD ETF (Symbol: JPLD) where we have detected an approximate $314.4 million dollar inflow -- that's a 14.2%... Full story

Yahoo Finance • 3 months ago

A Fresh Look at Ligand Pharmaceuticals (LGND) Valuation Following $400 Million Convertible Note Offering and Capital Structure Shift

If you have been watching Ligand Pharmaceuticals (LGND), the $400 million convertible note offering completed this month might have made you sit up and pay attention. Not only did the company finalize this sizable senior unsecured notes de... Full story

Yahoo Finance • 3 months ago

Ligand Pharmaceuticals stock hits 52-week high at $157.54

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), with a market capitalization of $3.1 billion, has reached a significant milestone with its stock hitting a 52-week high of $157.54. According to InvestingPro analysis, the stock is curren... Full story

Yahoo Finance • 3 months ago

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcom... Full story

Yahoo Finance • 4 months ago

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “note... Full story

Yahoo Finance • 4 months ago

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “no... Full story

Yahoo Finance • 4 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth

Ligand Pharmaceuticals (NASDAQ:LGND [https://www.chartmill.com/stock/quote/LGND]) reported second-quarter 2025 earnings that surpassed analyst expectations, driven by strong royalty revenue growth. Despite the beat, the stock showed muted... Full story

Yahoo Finance • 4 months ago

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1... Full story

Yahoo Finance • 4 months ago

Ligand Pharmaceuticals Q2 2025 Earnings Preview

* Ligand Pharmaceuticals (NASDAQ:LGND [https://seekingalpha.com/symbol/LGND]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. * The consensus EPS Estimate is $1.42 [https://seekingalpha.com/sym... Full story

Yahoo Finance • 4 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private p... Full story

Yahoo Finance • 4 months ago

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference... Full story

Yahoo Finance • 5 months ago

3 Stocks That May Be Trading Below Estimated Value In July 2025

As the U.S. stock market hovers near record highs, investors remain cautious amid ongoing trade policy uncertainties and fluctuating economic indicators. In this environment, identifying stocks that may be trading below their estimated val... Full story